AMGEN Inc

NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024

AMGN Articles

The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
24/7 Wall St. has put together a preview of Boeing, PepsiCo and other top companies scheduled to report their quarterly results on Wednesday.
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
The February 28 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
The February 15 short interest data have been compared with the previous report, and short interest increased in all the selected biotech stocks.
One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is the large cap biotechs.
The top analyst upgrades, downgrades and initiations seen on Wednesday include Broadcom, Canadian Solar, Goldman Sachs, TripAdvisor and Wal-Mart.
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Amgen Inc. (NASDAQ: AMGN) reported its fourth-quarter financial results after the markets closed on Thursday. This biotech giant posted $2.89 in earnings per share (EPS) and $5.97 billion in revenue,...
Although this earnings season has been relatively positive, the Dow has stepped away from its 20,000 mark, and it seems the animal spirits powering this rally might not be as positive as they once...